| Literature DB >> 33800955 |
Kaya E Witte1,2, Oliver Hertel3,4, Beatrice A Windmöller1,2, Laureen P Helweg1,2, Anna L Höving1,5, Cornelius Knabbe2,5, Tobias Busche4, Johannes F W Greiner1,2, Jörn Kalinowski4, Thomas Noll3,4, Fritz Mertzlufft2,6, Morris Beshay2,7, Jesco Pfitzenmaier2,8, Barbara Kaltschmidt1,2,9, Christian Kaltschmidt1,2, Constanze Banz-Jansen2,10, Matthias Simon2,11.
Abstract
Cancer stem cells (CSCs) are crucial mediators of tumor growth, metastasis, therapy resistance, and recurrence in a broad variety of human cancers. Although their biology is increasingly investigated within the distinct types of cancer, direct comparisons of CSCs from different tumor types allowing comprehensive mechanistic insights are rarely assessed. In the present study, we isolated CSCs from endometrioid carcinomas, glioblastoma multiforme as well as adenocarcinomas of lung and prostate and assessed their global transcriptomes using full-length cDNA nanopore sequencing. Despite the expression of common CSC markers, principal component analysis showed a distinct separation of the CSC populations into three clusters independent of the specific type of tumor. However, GO-term and KEGG pathway enrichment analysis revealed upregulated genes related to ribosomal biosynthesis, the mitochondrion, oxidative phosphorylation, and glycolytic pathways, as well as the proteasome, suggesting a great extent of metabolic flexibility in CSCs. Interestingly, the GO term "NF-kB binding" was likewise found to be elevated in all investigated CSC populations. In summary, we here provide evidence for high global transcriptional similarities between CSCs from various tumors, which particularly share upregulated gene expression associated with mitochondrial and ribosomal activity. Our findings may build the basis for identifying novel therapeutic strategies targeting CSCs.Entities:
Keywords: cancer stem cells; endometrioid carcinoma; glioblastoma multiforme; lung adenocarcinoma; mitochondrion; nanopore sequencing; prostate adenocarcinoma; ribosome
Year: 2021 PMID: 33800955 PMCID: PMC7962028 DOI: 10.3390/cancers13051136
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.639